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Inhibition of sirtuin 2 (SIRT2) deacetylase mediates
protective effects in cell and invertebrate models of
Parkinson’s disease and Huntington’s disease (HD).
Here we report the in vivo efficacy of a brain-perme-
able SIRT2 inhibitor in two genetic mouse models
of HD. Compound treatment resulted in improved
motor function, extended survival, and reduced brain
atrophy and is associated with marked reduction
of aggregated mutant huntingtin, a hallmark of HD
pathology. Our results provide preclinical validation
of SIRT2 inhibition as a potential therapeutic target
for HD and support the further development of
SIRT2 inhibitors for testing in humans.
INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant monoge-
netic neurodegenerative disorder characterized by progressive
neuronal loss, motor dysfunction, emotional disturbances,
dementia, weight loss, and premature death (Young, 2003).
Disease is caused by an expansion of CAG-triplet repeats within
exon 1 of the HD gene, which is translated into mutant huntingtin
protein with pathologically extended polyglutamines prone to
misfolding and aggregation (The Huntington’s Disease Collabo-
rative Research Group, 1993). Although huntingtin, a predomi-
nantly cytoplasmic protein of uncertain function, is ubiquitously
expressed in the body and brain, the earliest neuropathological
changes are found in the neostriatum and cerebral cortex (Rosas
et al., 2008). Intracellular aggregates containing misfolded hun-
tingtin can be readily detected in brain both presymptomatically
and throughout the course of the disease; however, the role for
polyglutamine aggregation in neurodegeneration has not been
resolved (Truant et al., 2008). It has become evident that mutant
huntingtin perturbs multiple biochemical pathways; however, no
dominant neurodegenerative mechanism has emerged (Hersch
and Rosas, 2008). Although preclinical studies in HD mouse
models have identified candidate therapeutics, there is not yet1492 Cell Reports 2, 1492–1497, December 27, 2012 ª2012 The Auta neuroprotective therapy demonstrated to slow or halt disease
progression in human HD.
The sirtuin family, which includes seven mammalian nicotin-
amideadeninedinucleotide (NAD)+-dependent enzymes (SIRT1–
SIRT7), has received much attention in recent years, due to their
diverse physiological functions in metabolism, aging, and age-
related human diseases (Donmez and Guarente, 2010). The
second familymember, sirtuin 2 (SIRT2), acts as anNAD+-depen-
dent deacetylase on a variety of histone and nonhistone sub-
strates, including a major component of microtubules, a-tubulin
(North et al., 2003; Vaquero et al., 2006). SIRT2 is a highly abun-
dant protein in the adult brain, where an alternatively spliced
isoform, SIRT2.2, is preferentially expressed (Maxwell et al.,
2011). In the brain, SIRT2 expression is detected in oligodendro-
cytes (Beirowski et al., 2011; Ji et al., 2011) and neurons (Luthi-
Carter et al., 2010; Maxwell et al., 2011), although the protein
function(s) remain elusive. In previous studies, genetic or phar-
macological inhibition of SIRT2 in primary neuronal and inverte-
brate animal models of Parkinson’s disease and HD rescued
neurotoxicity mediated by the causative a-synuclein and hun-
tingtin (Htt) proteins (Luthi-Carter et al., 2010; Outeiro et al.,
2007; Pallos et al., 2008). In primary neuronal HD models, inhibi-
tion of SIRT2 reducesmutant huntingtin aggregates, and, in part,
the neuroprotection was achieved by transcriptional repression
of cholesterol biosynthesis (Luthi-Carter et al., 2010).Conversely,
constitutive genetic inhibition in HD transgenic mice was not
neuroprotective and did not affect polyglutamine aggregation
(Bobrowska et al., 2012). In addition, a null SIRT2 genetic back-
ground or acute pharmacological inhibition did not affect tran-
scriptional expression of cholesterol biosynthesis enzymes in
the R6/2 HD mouse model (Bobrowska et al., 2012).
Here we utilized several preclinical target validation paradigms
and examined the in vivo efficacy of SIRT2 inhibition in HD
mouse models, using chronic pharmacological treatment.
We took advantage of a recently developed brain-permeable
selective SIRT2 inhibitor 3-(1-azepanylsulfonyl)-N-(3-brom-
phenyl) benzamide (AK-7) (Taylor et al., 2011), which is neuro-
protective in vitro and reduces polyglutamine inclusions and
cholesterol levels in neurons. Despite suboptimal pharmacolog-
ical properties, AK-7-mediated neuroprotection in vitro washors
achieved at doses comparable with brain concentrations in
wild-type and HD mice, followed by acute treatment (Taylor
et al., 2011). These results prompted us to examine the in vivo
efficacy of AK-7 using two well-characterized genetic mouse
models of HD.
Mousemodels of HD, recapitulating key pathological features,
have been developed and successfully used for preclinical
testing of therapeutics that have proceeded to clinical trials.
For this study, we employed the widely studied R6/2 mouse
model, where expression of multiple mutant exon 1 Htt frag-
ments with 150 CAG repeats results in a robust neurological
phenotype and premature death at approximately 100 days of
age (Stack et al., 2005). We also used the more genetically accu-
rate 140 CAG full-length Htt knockin model, which manifests
a mild neurological phenotype and has a normal life span (Me-
nalled et al., 2003). Using comprehensive outcome measures
to assess efficacy, we demonstrate that chronic treatment with
brain-permeable SIRT2 inhibitor AK-7 resulted in improved
motor function, extended survival, and reduced brain atrophy
in HD mice. Furthermore, the treatment benefits are associated
with significant reduction of mutant huntingtin aggregates in
HD brain. Our study strongly advances the preclinical validation
of SIRT2 inhibition as a neuroprotection target for HD. It also
provides a rationale for the development of SIRT2 inhibitors
with improved pharmacological properties that could be
advanced to human clinical trials.
RESULTS
Design of AK-7 Drug Trials in HD Mouse Models
First, we assessed the efficacy of AK-7 treatment in the R6/2
mouse model. The comparative analysis and quantification of
the expression levels of SIRT2 isoforms in cortical tissues of
R6/2 mice as well as knockin HD mice by western analysis
showed their clear presence in target tissue (Figure S1). There
were no progressive changes detected in SIRT2 levels in R6/2
or 140 CAG mice as they age, suggesting that the levels of
SIRT2 were not modified by disease. The compound synthesis
scheme for the study is shown in (Figure S2). In the acute toxicity
studies, the compound was safe up to 2,500 mg/kg, as no
mortality was observed up to this dose. For chronic drug-
treatment, doses of 10, 20, and 30 mg/kg were selected to
assess AK-7 efficacy in the phenotypic study. Given the limited
brain metabolic stability of AK-7 (half-life 2 h) (Taylor et al.,
2011), the compound and vehicle control treated-mice were
administered by intraperitoneal injections twice daily. The
20 mg/kg dose was used for neuropathological and biochemical
studies once phenotypic benefits were detected in both models
at that dose. Treatment was initiated in mice at 4 weeks of age
and continued up to 14 weeks or otherwise specified.
AK-7 Improves the Behavior and Neuropathological
Phenotype and Extends Survival of R6/2 HD Mice
AK-7-treated R6/2 mice performed significantly better than
vehicle-treated littermates on the accelerating rotarod at 8 and
11 weeks of age (Figure 1A). Latency to fall was increased by
29% at 8 weeks of age with AK-7 treatment at the 10 mg/kg
dose and by 44% at 11 weeks of age with AK-7 treatment atCell Re10 and 20 mg/kg doses. Values were significant only at the
age of 11 weeks.
AK-7 at the 10 mg/kg dose was also effective in extending the
survival of R6/2 mice (Figure 1B). Mean survival of placebo-
treated R6/2 mice was 94.8 ± 5.4, as compared with 109.2 ±
2.6 in AK-7-treated (10 mg/kg) mice; mean survival of treated
R6/2 mice was increased by 13.2% (Figure 1C). At the 20 mg/
kg dose, treatment with AK-7 caused a nonsignificant trend
toward survival extension. No effect of the 30 mg/kg dose on
survival was observed, possibly due to systemic toxicity at this
high dose.
AK-7 Ameliorates HD Neuropathology in R6/2 Mice
To assess the biological effects of AK-7 on neuropathology, mice
treated with 20 mg/kg of AK-7 were sacrificed at 12 weeks of
age. We selected the highest tolerable dose (20 mg/kg), for
which there was evidence of clinical efficacy in both models, to
examine effects on neuropathology in the brain. Unbiased
stereological methods were used to measure the striatal and
neuronal atrophy. The morphometric analysis showed a small
but statistically significant improvement in both total striatal
volume and striatal neuronal volume (Figures 1D–1F), which
were increased by 9% and 15%, respectively, confirming the
neuroprotective effects of AK-7 treatment. The average volume
of striatal neuronal cell bodies in wild-type mice was 640 ±
22.57 mm3, as compared with 410 ± 21.6 mm3 in 12-week-old
R6/2 mice. AK-7-treated (20 mg/kg) R6/2 mice had amean stria-
tal neuronal cell body volume of 470 ± 10.03 mm3, which was
significantly greater than placebo-treated R6/2 control mice.
AK-7 Reduces the Polyglutamine Aggregation in
R6/2 Brain
In the previous in vitro studies, inhibition of SIRT2 has been
demonstrated to reduce mutant huntingtin aggregates, and, in
part, the neuroprotectionwas achievedby transcriptional repres-
sion of cholesterol biosynthesis. Here we examined the effects
of AK-7 treatment on polyglutamine aggregates and cholesterol
levels in the R6/2 brain. Immunohistochemical analysis of the
striatal sections showed a marked reduction in aggregate size
in the brain of AK-7-treated HD mice (Figure 2A), and stereolog-
ical quantification demonstrated a 35% reduction in aggregate
volume. The mean nuclear aggregate volume in AK-7-treated
mice was 8.99 3 104 ± 0.48 mm3, as compared with 13.72 3
104 ± 0.56 mm3 in placebo-treated R6/2 (Figure 2B). AK-7 treat-
ment did not affect aggregate number (Figure 2C) or significantly
change soluble levels of mutant Htt, measured by a highly sensi-
tive homogeneous time-resolved fluorescence (HTRF) method
(Figure 2D) (Moscovitch-Lopatin et al., 2010). Nevertheless,
altogether the results suggest a significant reduction of aggre-
gated polyglutamine levels in compound-treated R6/2 brains.
Efficacy of AK-7 in 140 CAG Knockin HD Mice
We next assessed the effects of AK-7 treatment in the 140
CAG knockin Htt mouse model, using the same dosing regimen
of 10, 20, and 30 mg/kg twice daily. Treatment was started at
4 weeks of age and continued until sacrifice. We observed
a significant improvement in motor activity of 140 CAGmice with
AK-7 treatment (Figures 3A and 3B). Compared to wild-typeports 2, 1492–1497, December 27, 2012 ª2012 The Authors 1493
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Figure 1. Efficacy of AK-7 in R6/2 Mouse
Model of HD
(A) AK-7 ameliorates motor deficits in HD mice.
Latency to fall was increased by 37% at 11 weeks
of age (vehicle treated mice = 81 s, AK-7 (10 mg/
kg) treated mice = 129 s). Values represent
geometric mean ± 95% confidence interval. n =
10–15; * p% 0.05; **, p% 0.01.
(B and C) Kaplan–Meier probability of survival
analysis (B) and the column graph (C) shows that
AK-7 treatment significantly extends the survival
of R6/2 mice by 13.2%; n = 10–11. Data were
analyzed using Gehan–Wilcoxon test with Graph
Pad prism (B) (p = 0.0387) and GLM procedure in
SAS software (C) (p = 0.0280).
(D and E) Stereological quantification of total
striatal volume and neuronal cell body volume.
AK-7 treatment (20 mg/kg/12 h) improves the
total striatal volume of HD mice by 9% (p =
0.044) and rescues the shrinkage of striatal
neuronal cell body volume by 15% (p = 0.033).
Data represent mean ± SEM, n = 8–10;
***, p % 0.001.
(F) Thionin-stained sections of neostriatum
from a wild-type littermate mouse (right),
a placebo-treated R6/2 mouse (center), and an
AK-7-treated R6/2 mouse (left) at 12 weeks of
age. There is evidence of neuronal atrophy in
the untreated R6/2 mouse with relative pres-
ervation of neuronal atrophy in the AK-7-treated
mouse. The arrowheads represent healthy
neurons in wild-type, shrunken neurons in
untreated R6/2 mice, and relatively preserved
neurons in AK-7-treated R6/2 mice (scale bars,
25 mm).
See also Figures S1 and S2.mice, there was a significant decrease in motor activity in
untreated 140 CAG mice, as characterized by distance traveled
(Figure 3A) and increase in resting time (Figure 3B), starting at
2 months through 5 months (p < 0.01). In contrast, AK-7-treated
140 CAG mice showed motor performance changes that paral-
leled untreated wild-type mice, with the 20 mg/kg dose being
most effective and significantly different from untreated 140
CAG mice (p < 0.01). Both the 10 mg/kg and 30 mg/kg doses
were only significant at 2- and 3-month treatment time intervals
(p < 0.01). The administration of AK-7 at the 20 mg/kg dose, as
established in behavioral studies, markedly reduced the aggre-
gate number in the striatum of 140 CAG mice at 6 months by
greater than 50% (untreated 140 CAG mice: 4.31 3 106 ± 1.07,
AK-7-treated 140 CAG mice: 2.01 3 106 ± 0.63; p < 0.01)
(Figures 3C and 3D). The results in this second HDmouse model
demonstrate a significant reduction of aggregated polyglut-
amines in compound-treated brains and correlates with the effi-
cacy of AK-7 observed in the behavioral studies.
DISCUSSION
In this study, treatment with AK-7 significantly improved the
neurological phenotypes in both truncated and full-length HD1494 Cell Reports 2, 1492–1497, December 27, 2012 ª2012 The Autmouse models, despite its limited potency in vitro and subop-
timal pharmacological properties. Remarkably, the therapeutic
benefits were seen across outcome measures and included
improvement of motor behavior, extension of survival, and
neuroprotection, particularly in the more fulminant R6/2 disease
model, where pathology is driven by the expression of six trans-
genes and in which the truncated mutant huntingtin aggregates
quite avidly. Three compound doses, 10, 20, and 30mg/kg, were
tested in both mouse models prior to an analysis of neuropatho-
logical sequelae. Both the 10 mg/kg and 20 mg/kg doses were
effective in improving motor performance and survival in the
R6/2 mice. The 20 mg/kg dose was found most efficacious in
the behavioral studies in 140 CAG knockin mice, while 10 and
30 mg/kg doses were less effective in this model. Effects on
neuropathology were assessed in mice treated with 20 mg/kg,
the highest tolerated dose in which there was clinical evidence
for efficacy in both models. The significant improvement of
neuropathology, correlated with a 35% reduction in inclusion
volumes, was observed in R6/2 mice, albeit lower doses may
be better tolerated in this mouse model. Notably, the AK-7
reduction of inclusion volumes in the R6/2 brain compares simi-
larly to the effects of the neuroprotective aggregation inhibitor
C2-8 (Chopra et al., 2007). Intriguingly, selective SIRT2 inhibitionhors
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Figure 2. Compound Treatment-Mediated
Changes in R6/2 Mouse Brain
(A) AK-7 decreases the size of striatal neuronal
intranuclear huntingtin aggregates. Immuno-
detection of intraneuronal huntingtin aggregates
by using EM48 antibody (arrows) in the neo-
striatum of 12-week-old R6/2 mice with and
without AK-7 treatment (scale bars, 25 mm).
(B) Stereological counts of striatal intraneuronal
aggregates in R6/2 mice. AK-7 treatment signifi-
cantly reduced (35%) the striatal nuclear aggre-
gate volume in R6/2 mice.
(C and D) AK-7 treatment had no effect on mean
aggregate count or levels of soluble mutant hun-
tingtin exon 1 fragments, as detected by highly
sensitive HTRF method. Error bars indicate SEM;
***, p% 0.001; n = 8–10.
See also Figures S1 and S2.activity in vitro has been shown for C2-8 or its structural analogs
(Taylor et al., 2011), suggesting a SIRT2 inhibition-dependent
neuroprotective mechanism for this compound or its metabo-
lites. In 140 CAG mice, the effects of AK-7 on aggregation was
even more robust, leading to reduction of inclusion numbers
by 50%, and is consistent with the genetic and pharmacological
properties of SIRT2 inhibition observed in in vitro HD neurons
(Luthi-Carter et al., 2010; Taylor et al., 2011). Altogether, the
data from both mouse models demonstrate a correlation
between animal behavioral efficacy and improved neuronal
health and the reduced presence of aggregated polyglutamines
in the HD brain, which likely represents a proximal mechanism of
neuroprotection. Since AK-7 treatment was beneficial in two
HD mouse models, the data also suggests the therapeutic
potential of sulfobenzoic acid derivatives in humans. To develop
more potent SIRT2 inhibitors with superior pharmacological
properties, we plan to repurpose a previously identified sub-
scaffold (C2-8) for bioactive sulfobenzoic acid derivatives (Choi
et al., 2012).
The role of SIRT2 as a potential therapeutic target for HD
has been recently investigated by analysis of F1 progeny from
the genetic cross of R6/2 and SIRT2 knockout (KO) mouse
strains (Bobrowska et al., 2012). In contrast to our results, that
study showed no apparent benefits of SIRT2 negative back-
ground on HD pathology, including loss of body weight,
deficiency in motor performance, or aggregation. The study
also revealed no detectable phenotype in SIRT2 KO mice.
Genetic knockouts remove target(s) from known and unknown
protein complexes, disrupt target-specific signaling pathways,
cause structural reshuffling, and often result in embryonic
lethality or in a lack of phenotype (Barbaric et al., 2007). This is
fundamentally different than gene silencing, due to the transient
action of small molecule drugs, which are typically rapidly disen-
gaged from the target and degraded, leaving the target proteins
intact. It is clear that a discrepant outcome from genetic and
pharmacological manipulations is not limited to SIRT2. ForCell Reports 2, 1492–1497, Deexample, no improvement of neurological
phenotype has been observed in F1
progeny from the genetic cross of R6/2and heterozygote HDAC3 knockout mice (Moumne´ et al.,
2012). In contrast, the benefits of treating R6/2 mice with dual
HDAC1/3 inhibitors have been achieved by preferentially target-
ing HDAC3 (Jia et al., 2012a, 2012b), although polypharmaco-
logical properties of small molecules add complexity to the
data interpretation.
Altogether, we believe that preclinical efficacy trials in HDmice
using small molecules models drug-treatment of human patients
reasonably well and are thus applicable for target and thera-
peutic validation studies. To proceed with the clinical develop-
ment of a SIRT2 inhibitor for clinical use, it remains imperative
to identify structurally diverse SIRT2 inhibitors and to validate
the efficacy of these entities in mouse models of HD and other
neurodegenerative diseases.
EXPERIMENTAL PROCEDURES
Animals
Female R6/2mice used in the study were generated by backcrossingmale R6/
2 (available from The Jackson Laboratory, Bar Harbor, ME) with C57BL/6 X
CBA F1 females. 140 CAG knockin mice were also maintained on B6CBA
background. Mice were genotyped by PCR using tail-tip DNA and were
housed five per cage under standard conditions with ad libitum access to
water and food. To ensure homogeneity of experimental cohorts, mice from
the same F generation were systemically assigned to experimental groups,
such that age, weight, and CAG repeat lengths were balanced. All animal
experiments were carried out in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals and were approved
by local animal care committee.
Drug Treatment
Mice were administered different doses of AK-7 (10, 20, and 30 mg/kg)
by intraperitoneal injections twice daily starting from 4 weeks of age in
both the R6/2 and 140 CAG HD mouse models. The drug suspension
was 2made fresh daily. Body weights were recorded weekly at the same
time of day. Mice were assessed for morbidity and mortality twice daily. The
criterion for euthanasia was the point in time when mice could no longer right
themselves within 30 s after being placed on their sides. Deaths that occurred
overnight were recorded the following morning.cember 27, 2012 ª2012 The Authors 1495
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Figure 3. Efficacy of AK-7 in 140 CAG
Knockin Htt Mouse Model
(A and B) Behavioral test. Open field analysis of
AK7 administration in 140 CAG mice shows a sig-
nificant improvement at all the doses in (A) distance
traveled and (B) resting time, with 20 mg/kg as the
most efficacious dose. Symbols: filled circles, un-
treated wild-type; filled diamond, untreated CAG
140; filled squares, 10 mg/kg/12h; open triangles,
20 mg/kg/12h; and open circles, 30 mg/kg/12h.
(C and D) Aggregation. There was a significant
reduction in huntingtin aggregates (untreated
140 CAGmice: 4.313 106 ± 1.07, AK-7 20 mg/kg-
treated 140 CAG mice: 2.01 3 106 ± 0.63; p <
0.01). Error bars indicate SEM. Arrowheads
represent intraneuronal huntingtin aggregates.Behavioral Analyses
Motor performance in R6/2 mice was assessed using an accelerating rotarod
(Stoelting, Ugo Basile, Biological Research apparatus; Varese, Italy) at 5, 8,
and 11 weeks of age. At the beginning of each week, mice were trained for
30 s at a slow speed of 4.5 rpm. Subsequently, three trials were performed
for three consecutive days. In each trial, mice were placed onto the rotarod
at a constant speed of 4.5 rpm for 5 s, which then accelerated at a constant
rate until a terminal angular velocity of 45 rpm was reached. The latency to
fall from the rotarod was recorded for each mouse, and the average of three
trials was used for statistical analysis. Data were analyzed by using the mixed
procedure in SAS version 9.1 software. Results were considered statistically
significant at p < 0.05.
Behavioral testing for the wild-type and 140 CAGmice was performed using
open field boxes (Opto-Varimex Unit, Columbus Instruments, OH, USA).
Measurements were made for 30 min after 10 min of acclimation to the box.
Counts of horizontal and vertical motion activities were monitored and quanti-
tative analysis of locomotor activities (resting and ambulatory times) was
assessed. The open-field box was cleaned before testing each mouse. Mice
were coded and investigators were blinded to the genotype and analysis.
Testing started on week six and was performed every other week until the
mice could no longer participate.
Histology
At 90 days of age and 6 months, R6/2 and 140 CAG mice, respectively,
were deeply anesthetized and then transcardially perfused with 2% parafor-
maldehyde in 0.1 M phosphate buffer (pH 7.4). Brains were postfixed with
perfusant for 2 days, cryoprotected in a graded series of 10% and
20% glycerol/2% DMSO, and serially sectioned at 50 mm using a SM
2000R freezing microtome (Leica, Wetzlar, Germany). Every eighth section
was stained with thionin for striatal volume and neuronal volume analysis.
For aggregate immunohistochemistry, floating sections of forebrain at the
level of crossing of the anterior commissure were stained with EM48
(dilution, 1:2,000) for 2 days, washed, and incubated with biotinylated
secondary antibody and visualized using the Vectastain ABC kit (Vector
Laboratories, Burlingame, CA). Sections were mounted in aqueous solution
(Fluoromount G; Southern Biotech, Birmingham, AL) to prevent z axis
shrinkage. No signal was detected in the controls, in which primary antibody
was omitted. Data were analyzed by ANOVA using the generalized linear
model (GLM) procedure in SAS software. Results were considered statisti-
cally significant at p < 0.05.1496 Cell Reports 2, 1492–1497, December 27, 2012 ª2012 The AuthorsStereology
All analyses were performed blind by using unbi-
ased stereological approaches, Stereo-Investi-
gator software (MicroBrightField, Williston, VT),
and a Leica DMLB microscope with a motorized
stage, as described previously (Chopra et al.,
2007). Striatal volumes were estimated on every
eighth coronal section by using the Cavalierimethod. Stereological counts of aggregate number and volumes of cell bodies
and intranuclear aggregates were obtained from the neostriatum at the level of
the anterior commissure using the optical fractionator and nucleator methods,
respectively. Data were analyzed by ANOVA using the GLM procedure in SAS
software. Results were considered statistically significant at p < 0.05.
Time-Resolved Fluorescence Resonance Energy Transfer Assay for
Soluble Mutant Huntingtin
Brain tissues were homogenized in 10X volume lysis buffer (0.4% Triton X-100
in PBS and 0.1% Halt Protease Inhibitor Cocktail [Thermo Scientific]) and
lysate (5 mg/well) were mixed with a reaction buffer (NaH2PO4 (50 mM, pH
7.4), NaF (400mM), BSA (0.1%w/v), and Tween 20 (0.05% v/v), containing flu-
orophore conjugated antibodies (2B7-Tb, MW1-Alexa 488). The HTRF signal
was read on a VICTORX5 plate reader (Perkin Elmer) after 1 hr of incubation
at 4C. After excitation of the Tb donor at 320 nm, emission signals of Alexa488
were detected at 510 nm. The signal resulting from the emission of the Tb was
measured at 615 nm and was used for normalization of potential signal
artifacts. The 510/615 nm ratio values reflect the relativemutant Htt concentra-
tion. Data were analyzed by ANOVA using the GLM procedure in SAS
software. Results were considered statistically significant at p < 0.05.
For additional details, please see the Extended Experimental Procedures.
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